InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Secures $1M Premium Equity Funding to Advance Age-Reversal Therapies
Telomir Pharmaceuticals (NASDAQ: TELO) has raised $1 million in equity funding from The Starwood Trust through a common stock transaction priced at $7 per share, a 20% premium to the closing price. This follows an undrawn $5 million non-dilutive line of credit from The Starwood Trust earlier this year, reinforcing confidence in Telomir’s strategy. The funding supports Telomir’s innovative pipeline, led by its breakthrough compound,…